The NHS is not ready for a new era of diagnosing and treating Alzheimer’s disease, nor is the UK “keeping pace with the science”, experts have warned.

The Alzheimer’s landscape is set to be transformed in the coming years thanks to new drugs and blood tests, yet a group of 40 researchers said that without rapid reform, the potential of these “major innovations” will not be realised.

Writing in a series of papers published in The Lancet , the researchers also claim the “game-changing” medications donanemab and lecanemab slow the progression of Alzheimer’s as effectively as treatments do for other conditions such as cancer, rheumatoid arthritis and multiple sclerosis. New Feature

In Short

Quick Stories. Same trusted journalism.

Both treatments received a UK licence last year,

See Full Page